This segment focuses on the preparation and cryopreservation of various cell types, including umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. The company employs advanced cryopreservation techniques to ensure cell viability and functionality for future therapeutic applications. Research efforts are directed towards optimizing cell isolation, expansion, and storage protocols to enhance the quality and efficacy of cell-based therapies. This segment plays a crucial role in providing a readily available source of cells for regenerative medicine and personalized healthcare solutions, addressing a wide range of potential clinical applications from hematological disorders to autoimmune diseases.

Vcanbio's genetic testing segment offers a comprehensive suite of diagnostic services, including non-invasive prenatal genetic testing (NIPT), safe medication guide gene testing for children and adults, disease genetic testing, and disease susceptibility gene testing. The company utilizes advanced sequencing technologies and bioinformatics analysis to provide accurate and reliable genetic information for personalized healthcare decisions. Research and development efforts are focused on expanding the range of genetic tests offered and improving the accuracy and efficiency of testing methodologies. This segment aims to empower individuals and healthcare providers with valuable insights into genetic predispositions, enabling proactive disease prevention and personalized treatment strategies.

This segment is dedicated to the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and experimental synthetic agents. Vcanbio leverages its expertise in cell and gene engineering to develop innovative biopharmaceutical products for various therapeutic applications. Research efforts are focused on identifying novel drug targets, developing targeted therapies, and optimizing manufacturing processes to ensure product quality and scalability. This segment aims to address unmet medical needs by developing cutting-edge biopharmaceutical solutions for a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The company also focuses on in vitro diagnostic reagents and medical devices.